Astrazeneca Boosts Pipeline With $2.7Bn Acquisition

Di: Everly

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC).

AstraZeneca raised its annual earnings forecast on Thursday, helped by strong demand for its cancer drugs, and moved to boost its pipeline in the booming anti-obesity market with a deal costing up

AstraZeneca scores new goal on the pipeline front, adding its first AI ...

Astra’s radiopharma Fusion

AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel

AstraZeneca. has taken another step to refill its depleted product pipeline by agreeing to pay $575m for the respiratory business of Takeda.. The acquisition gives the UK

AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
Mergers & Acquisitions by Top Biotechnology Companies
Acquisition of Fusion completedAcquisition of Gracell completed

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which

A big leap in total revenues is a sign AstraZeneca is well on its way to hitting its goal of $80bn by 2030. If it keeps growing at this rate it’ll break through the $100bn threshold

AstraZeneca Plc is licensing a drug from China’s CSPC Pharmaceutical Group Ltd that it hopes will treat high cholesterol, as the pharma company seeks to bolster its cardiovascular pipeline.

AstraZeneca Buys Fusion for Up to $2.4 Billion — Update

STC-004 works by blocking the Nav1.8 sodium channel, a voltage-gated channel primarily found in pain-sensing neurons. The asset could have a lucrative market potential,

The latest news, analysis and opinion on AstraZeneca PLC. In-depth analysis, industry insights and expert opinion In-depth analysis, industry insights and expert opinion Accessibility help

AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage

AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. ZS Pharma

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP

In July 2021, AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc for $13.3 billion in cash and 236,321,411 new AstraZeneca shares. Alexion specializes in

Astrazeneca boosts cardiovascular pipeline with licensing deal
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4 Billion
AstraZeneca completes Icosavax acquisition for $1.1bn
Press Release: AstraZeneca to acquire MedImmune
AstraZeneca: A strong pipeline is a big tailwind

AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday to acquire longtime biotechnology

At AstraZeneca, we aim to revolutionise cancer care with our portfolio, our pipeline and our people. We follow the science, wherever it takes us, in pursuit of the best medicines. Through

Success in performance, delivery and the pipeline have each contributed to another year of progress for pharmaceutical giant AstraZeneca PLC (LON: AZN) which is

The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.

AstraZeneca PLC 12 November 2021 07:00 GMT Year to date and Q3 2021 results AstraZeneca reinforces its scientific leadership through exceptional pipeline delivery and the addition of

At AstraZeneca UK, you’ll gain insight into what it’s like to work with a global market leader, alongside some of the brightest minds in the industry, as part of a culture of collaboration that

AstraZeneca will acquire all outstanding equity of Neogene for a total consideration of up to $320m, on a cash and debt free basis. This will include an initial

AstraZeneca boosts heart, kidney business with $1.8 bln CinCor deal ...

With this acquisition, AstraZeneca complements its portfolio with Fusion’s pipeline of RCs, including their most advanced program, FPI-2265, a potential new treatment for patients with

Similarly, the guidance excludes the proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion) which is intended to become AstraZeneca’s rare disease unit and area of expertise.

AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition. The deal includes a candidate currently in phase 3 testing as a treatment for

Icosavax will function as an AstraZeneca subsidiary with operations in Seattle, US. Credit: rafapress/Shutterstock.com. AstraZeneca has concluded the acquisition of the US

The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional

GORT

Reviews